Acute lymphoblastic leukemia affects nearly 15% of pediatric cancer cases. A new drug PR-104 is active against the aggressive form of blood cancer.

UNSW Conjoint Richard Lock and Donya Moradi Manesh, based at the Children's Cancer Institute, have shown that a drug known as PR-1042 is effective against laboratory models of aggressive T-ALL.
"During the 10 years we've been funded under the NCI program, we've tested over 70 drugs and combinations, and PR-104 is one of the most exciting yet, with the potential to be fast-tracked into clinical trials for children," said Lock.
The team found that only the T cell subtype expressed high levels of AKR1C3, an enzyme that activates PR-104. The research team is in the process of examining the molecular biology behind AKR1C3, and trying to understand why T-ALL cells express very high levels of the enzyme.
Source-Medindia
MEDINDIA




Email










